On June 16, 2017, 107.3 m shares were listed on SIX.
In June 2017, 11.8 m shares issued through the conversion of the first tranche of the convertible loan provided by Cilag Holding AG, an indirect subsidiary of Johnson & Johnson, were listed. In November 2021, a second tranche of the convertible loan was converted and Cilag acquired 9.6 m shares of the Group. The remaining amount of the convertible loan may be converted into 29.1 m shares.
In July 2018, the Group privately placed 11.9 m new registered shares. Concurrently to the private placement of new shares, the Group issued CHF 200 m of senior unsecured convertible bonds, which were due to mature on July 17, 2024. On May 6, 2024, bondholders approved amendments to the terms of the bonds. The approved bond terms include an amended conversion price of CHF 6.00, extended maturity date of January 17, 2025, and the option to call the bonds at par, in full or in part, at any time upon giving ten trading days' notice.
In May 2020, the Group privately placed 11 m new registered shares.
In October 2020, the Group issued 23.8 m new registered shares.
In August 2021, the Group placed CHF 600 m senior unsecured convertible bonds due 2028 convertible into 19.0 m shares of the Group.
In January 2023, the Group created 10 m treasury shares.
Idorsia Ltd is part of the following indices: SPI, SPIEX, SPI ESG, SXSLI, SXI Life Sciences, SXI Bio+Medtech, and SSIRT.
Idorsia is traded under the following symbols: Reuters IDIA.S / Bloomberg IDIA:SW.